105355-25-7

Basic information

• Product Name: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester
• Synonyms: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester;Methyl 2-bromo-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionate;Methyl 2-bromo-3-(4-(2-(5-ethylpyridin-2-yl)ethoxy)phenyl)propanoate
• CAS NO: 105355-25-7
• Molecular Formula: C₁₉H₂₂BrNO₃
• Molecular Weight: 392.29
• EINECS: 1312995-182-4
• Mol File: 105355-25-7.mol

Chemical Properties

• Boiling Point: 484.971 °C at 760 mmHg
• Flash Point: 247.102 °C
• Appearance: /
• Density: 1.309
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: 2-8°C
• PKA: 5.53±0.22(Predicted)
• CAS DataBase Reference: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(105355-25-7)
• EPA Substance Registry System: 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester(105355-25-7)

Safety Data

• Hazardous Substances Data: 105355-25-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester is utilized as a pharmaceutical compound for its potential therapeutic properties. Its unique structure and functional groups may contribute to its activity against specific biological targets or diseases, making it a candidate for drug development.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester serves as an intermediate compound. Its versatile structure allows for further chemical modifications and transformations, facilitating the synthesis of more complex molecules with desired properties.
Used in Chemical Research:
2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester is employed in chemical research to study its reactivity, stability, and potential interactions with other molecules. This research can provide insights into the development of new synthetic methods, understanding of reaction mechanisms, and the discovery of novel applications for this compound.
Used in Specialty Chemicals Industry:
2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester is used as a specialty chemical in various industries, such as materials science, where its unique properties may be leveraged for the development of new materials with specific characteristics.
Note: The specific applications mentioned above are hypothetical and based on the general properties of complex organic compounds. The actual uses of 2-Bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]propionic acid methyl ester would depend on its specific characteristics and the outcomes of experimental research.

InChI:InChI=1/C19H22BrNO3/c1-3-14-4-7-16(21-13-14)10-11-24-17-8-5-15(6-9-17)12-18(20)19(22)23-2/h4-9,13,18H,3,10-12H2,1-2H3

Upstream product

• 85583-40-0 4-[2-(5-ethylpyridin-2-yl)ethoxy]aniline 
• 292638-85-8 acrylic acid methyl ester 
• 669716-58-9 2-[2-(4-bromophenoxy)ethyl]-5-ethyl-pyridine 
• 350-46-9 4-Fluoronitrobenzene 
• 85583-54-6 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene 
• 5223-06-3 5-ethyl-2-(2-hydroxyethyl)pyridine 

Downstream Products

• 105355-27-9 Pioglitazone 
• 914249-67-5 pioglitazone imino ether 
• 112529-15-4 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione hydrochloride 
• 101931-09-3 methyl 3-{4-[2-acetoxy-2-(5-ethyl-2-pyridyl) ethoxy]phenyl}-2-bromopropionate 
• 101931-00-4 5-{4-[2-(5-ethyl-pyridin-2-yl)-2-hydroxyethoxy]benzyl}-2,4-thiazolidinedione 
• 105355-26-8 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2-imino-4-thiazolidinone 
• 145350-19-2 methyl 2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate N-oxide 

Relevant articles and documents

Preparation method of piogelimide

The invention provides a preparation method of piogelimide, which comprises the following steps: by using 4-[2- (5-ethyl-2-pyridyl)ethyoxyl]nitrobenzene as a starting material, methanol as a solvent and Raney Ni as a catalyst, carrying out catalytic hydrogenation, carrying out pressure filtration on the reaction solution into hydrobromic acid to carry out acidification reaction, and adding cuprousoxide, methyl acrylate and acetone into the system; dropwise adding a sodium nitrite solution, drying the organic solvent by distillation under reduced pressure after the reaction is finished, addingammonia water, alkalifying the solution by using liquid caustic soda, and extracting the product by using ethyl acetate; and adding thiourea and sodium acetate into the ethyl acetate solution, performing heating reflux until the reaction is finished, cooling the reaction product, adding water, spin-drying the reaction product, and refining the product by using DMF to obtain a piogelimide finishedproduct. According to the method, the yield and purity of the product can be effectively improved, the raw material cost is greatly reduced, the production operation is simplified, the production efficiency is improved, and the influence on the environment is greatly reduced.

An improved process for pioglitazone and its pharmaceutically acceptable salt

An improved process for pioglitazone (1) is described. The process features high-yielding transformations employing inexpensive reagents and recoverable solvents.

Pioglitazone impurities

Methods of preparation of API pioglitazone were discussed from the point of view of impurities occurrence. Four real impurities (I-IV) of pioglitazone were prepared and characterized by means of NMR spectroscopy.

PROCESSES FOR THE PREPARATION OF PIOGLITAZONE OR SALTS THEREOF

The present invention provides processes for the preparation of highly pure pioglitazone or a salt thereof. In addition, the present invention provides pioglitazone or a salt thereof having about 0.1% or less of dehydropioglitazone impurity.

Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones

The synthesis of a series of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones is described. These compounds were evaluated for hypoglycemic and hypolipidemic activities in genetically obese and diabetic mice, yellow KK. 2-(2-Pyridyl)alkoxy derivatives were found to have much better hypoglycemic and hypolipidemic activities than 2-(3-pyridyl)- and 2-(4-pyridyl)alkoxy derivatives or even the previously reported compound, ciglitazone. The introduction of a hydroxyl group at the 2-position of the ethoxy chain potentiated the activities. Among the potent compounds, pioglitazone (AD-4833) was selected as a candidate compound.

Thiazolidinedione derivatives, useful as antidiabetic agents

Thiazolidinedione derivatives of the formula: STR1 and pharmacologically acceptable salts thereof are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for treatment of diabetes and hyperlipemia.